ELEKTA Company Profile (NASDAQ:EKTAY)

About ELEKTA (NASDAQ:EKTAY)

ELEKTA logo

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:EKTAY
  • CUSIP: N/A
  • Web: www.elekta.com
Average Prices:
  • 50 Day Moving Avg: $9.43
  • 200 Day Moving Avg: $9.47
  • 52 Week Range: $7.70 - $10.95
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 25.31
  • P/E Growth: 0.0000
Dividend:
  • Dividend Yield: 0.6%
 

Frequently Asked Questions for ELEKTA (NASDAQ:EKTAY)

What is ELEKTA's stock symbol?

ELEKTA trades on the NASDAQ under the ticker symbol "EKTAY."

How often does ELEKTA pay dividends? What is the dividend yield for ELEKTA?

ELEKTA announced a None dividend on Thursday, July 20th. Investors of record on Friday, August 25th will be given a dividend of $0.04 per share on Thursday, September 14th. The ex-dividend date is Wednesday, August 23rd. View ELEKTA's Dividend History.

How were ELEKTA's earnings last quarter?

ELEKTA (NASDAQ:EKTAY) released its quarterly earnings data on Wednesday, December, 4th. The company reported $0.07 EPS for the quarter. View ELEKTA's Earnings History.

Who are some of ELEKTA's key competitors?

How do I buy ELEKTA stock?

Shares of ELEKTA can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ELEKTA's stock price today?

One share of ELEKTA stock can currently be purchased for approximately $9.87.


MarketBeat Community Rating for ELEKTA (NASDAQ EKTAY)
Community Ranking:  1.5 out of 5 ( )
Outperform Votes:  25 (Vote Outperform)
Underperform Votes:  61 (Vote Underperform)
Total Votes:  86
MarketBeat's community ratings are surveys of what our community members think about ELEKTA and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ELEKTA (NASDAQ:EKTAY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating
Consensus Rating:Sell (Score: 1.00)
Consensus Price Target: N/A

Analysts' Ratings History for ELEKTA (NASDAQ:EKTAY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
12/7/2016Jefferies Group LLCDowngradeHold -> UnderperformN/AView Rating Details
12/8/2015Morgan StanleyDowngradeEqual Weight -> UnderweightN/AView Rating Details
9/2/2015DNB MarketsUpgradeHold -> BuyN/AView Rating Details
8/21/2015SwedbankDowngradeBuy -> NeutralN/AView Rating Details
(Data available from 7/21/2015 forward)

Earnings

Earnings History for ELEKTA (NASDAQ:EKTAY)
Earnings by Quarter for ELEKTA (NASDAQ:EKTAY)
Earnings History by Quarter for ELEKTA (NASDAQ EKTAY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2017Q4$0.02$295.66 millionViewListenView Earnings Details
12/4/2013Q3$0.07ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ELEKTA (NASDAQ:EKTAY)
Current Year EPS Consensus Estimate: $0.3300 EPS
Next Year EPS Consensus Estimate: $0.3900 EPS

Dividends

Dividend History by Quarter for ELEKTA (NASDAQ EKTAY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/20/2017None$0.048/23/20178/25/20179/14/2017
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for ELEKTA (NASDAQ:EKTAY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for ELEKTA (NASDAQ:EKTAY)
Latest Headlines for ELEKTA (NASDAQ:EKTAY)
Source:
DateHeadline
americanbankingnews.com logoELEKTA to Issue None Dividend of $0.04 (NASDAQ:EKTAY)
www.americanbankingnews.com - July 21 at 11:52 AM
seekingalpha.com logoViewRay: Initiate Strong Sell On Questionable Backlog, Product Inferiority, And Bankruptcy Concerns
seekingalpha.com - July 20 at 3:35 PM
americanbankingnews.com logoZacks: ELEKTA (NASDAQ:EKTAY) Receives Average Recommendation of "Sell" from Analysts
www.americanbankingnews.com - July 19 at 6:30 PM
seekingalpha.com logoViewRay Expands Across The World
seekingalpha.com - July 6 at 7:24 PM
finance.yahoo.com logoParkinson's Disease Patients are First to be Treated With Elekta's New Leksell Vantage Stereotactic System
finance.yahoo.com - June 28 at 3:11 AM
finance.yahoo.com logoIsala and Elekta Sign Long-term Partnership Agreement for Optimal Cancer Care
finance.yahoo.com - June 27 at 5:11 PM
finance.yahoo.com logoElekta Chooses Brainlab to Distribute Stereotactic Neurosurgical Solutions Within Selected Markets in Europe
finance.yahoo.com - June 26 at 5:54 PM
finance.yahoo.com logoFirst Patient in Canada Treated with Elekta's Leksell Gamma Knife Icon
finance.yahoo.com - June 22 at 10:08 AM
americanbankingnews.com logo ELEKTA (EKTAY) Given Consensus Recommendation of "Sell" by Brokerages
www.americanbankingnews.com - June 21 at 4:38 PM
finance.yahoo.com logoAlliance Cancer Care to Upgrade Cancer Care in Southeastern U.S. with Elekta Solutions
finance.yahoo.com - June 20 at 5:37 PM
finance.yahoo.com logoNew Data From the Elekta Lung Research Group Support the use of Stereotactic Body Radiation Therapy in Elderly Patients With Early-stage Lung Cancer
finance.yahoo.com - June 15 at 7:01 PM
americanbankingnews.com logoELEKTA (EKTAY) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - June 6 at 6:54 PM
finance.yahoo.com logoElekta shares fall after big Q4 earnings miss
finance.yahoo.com - June 1 at 5:38 PM
americanbankingnews.com logo ELEKTA (EKTAY) Given Average Rating of "Sell" by Analysts
www.americanbankingnews.com - May 30 at 7:54 AM
finance.yahoo.com logoElekta Radiosurgery Solutions Highlighted at International Stereotactic Radiosurgery Society Congress
finance.yahoo.com - May 26 at 5:33 PM
finance.yahoo.com logoElekta Unity, Transformative Magnetic Resonance Radiation Therapy (MR/RT) System, Debuts at ESTRO 36
finance.yahoo.com - May 6 at 10:44 AM
americanbankingnews.com logoZacks: ELEKTA (EKTAY) Receives Consensus Rating of "Sell" from Analysts
www.americanbankingnews.com - May 4 at 11:04 PM
americanbankingnews.com logoELEKTA (EKTAY) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 2 at 9:38 PM
finance.yahoo.com logoElekta to Showcase the Latest in Stereotactic Solutions at ESTRO 36
finance.yahoo.com - May 2 at 3:57 PM
finance.yahoo.com logoPatient in Germany is World's First to Receive Brachytherapy With Elekta's New Venezia Gynecological Applicator
finance.yahoo.com - April 26 at 11:29 PM
finance.yahoo.com logoElekta to Highlight Continued Innovation in Stereotactic Neurosurgery with Leksell Vantage Stereotactic System at AANS
finance.yahoo.com - April 24 at 4:48 PM
americanbankingnews.com logoZacks: ELEKTA (EKTAY) Receives Consensus Recommendation of "Sell" from Brokerages
www.americanbankingnews.com - April 17 at 6:18 PM
americanbankingnews.com logo ELEKTA (EKTAY) Receives Consensus Recommendation of "" from Brokerages
www.americanbankingnews.com - March 29 at 12:02 PM

Social

Chart

ELEKTA (EKTAY) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by MarketBeat.com Staff